Skip to main content

Advertisement

Table 5 Survival in trials comparing gemcitabine to gemcitabine plus platinum analog

From: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Reference Year Treatment regimen Median survival (mo) p HR 95% CI
Louvet 2005 Gemcitabine 7.1 0.13 0.82 0.64 – 1.05
   Gemcitabine (FDR) + Oxaliplatin 9.0    
Poplin 2006 Gemcitabine (standard) 4.9 -- 0.83* 0.69 – 1.00
   Gemcitabine (FDR) 6.0 -- 0.88** 0.73 – 1.05
   Gemcitabine (FDR) + Oxaliplatin 5.9    
Heinemann 2006 Gemcitabine 6.0 0.15 0.80 0.59 – 1.08
   Gemcitabine + Cisplatin 7.5    
Colucci 2002 Gemcitabine 5.0 0.48 0.87 0.58 – 1.29
   Gemcitabine + Cisplatin 7.5    
Viret 2004 Gemcitabine 6.7 0.73 0.92 0.59 – 1.45
   Gemcitabine + Cisplatin 8.0    
  1. FDR = fixed dose rate;
  2. * FDR Gemcitabine versus Gemcitabine
  3. ** GEMOX versus Gemcitabine